Genaissance to Market Genetic Tests Based on IP from U of Rochester and Mayo Clinic | GenomeWeb

NEW YORK, April 6 (GenomeWeb News) - Genaissance Pharmaceuticals said today that it has signed agreements with the University of Rochester and the Mayo Clinic for access to clinical research samples, associated data, and intellectual property around certain disease-associated mutations that it will use in developing genetic tests for cardiac disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.